Apollo Endosurgery Incの収益Y / Y
Apollo Endosurgery Incの収益Y / Yは何ですか。
Apollo Endosurgery Incの収益Y / Yは22.01%です。
収益Y / Yの定義は何ですか。
過去3年間の年間収益の伸びは、過去3年間で平均した1年間の収益成長率です。
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
NASDAQのセクタHealth Careにおける収益Y / Yの企業と比べるApollo Endosurgery Inc
Apollo Endosurgery Incは何をしますか。
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo Endosurgery Incと類似の収益y / y
- Bioconの収益Y / Yは21.97%です。
- Celesticaの収益Y / Yは21.97%です。
- Rayonierの収益Y / Yは21.97%です。
- Chen Xing Developmentの収益Y / Yは21.97%です。
- MS INTERNATIONAL plcの収益Y / Yは22.01%です。
- Hormel Foods Dl ,01465の収益Y / Yは22.01%です。
- Apollo Endosurgery Incの収益Y / Yは22.01%です。
- Barnesの収益Y / Yは22.02%です。
- Rane Engine Valveの収益Y / Yは22.02%です。
- DoubleVerifyの収益Y / Yは22.03%です。
- Vertex Pharmaceuticalsの収益Y / Yは22.03%です。
- Immutepの収益Y / Yは22.05%です。
- Immutepの収益Y / Yは22.05%です。